2011 MASCC/ISOO Annual Meeting Study Group Workshops

Workshops:  2019  |  2018  |  2017  |  2016  |   2015  |  2014  |  2013  |  2012  |  2011 

Issues In Controlling Nausea Associated With Cancer Chemotherapy
Chairs: Richard J. Gralla and Rebecca A. Clark‐Snow

With the development of newer antiemetics and the use of published evidence-based antiemetic guidelines, clinicians are able to prevent chemotherapy-induced emesis for many patients. However, nausea remains a significant problem. This interactive workshop, presented by the Antiemetics Study Group, addressed  the etiology of chemotherapy and cancer treatment-related nausea, including measurement tools, available treatments, and considerations for future research.

  • Richard J. Gralla (USA) and Jørn Herrstedt (Denmark). Discussion and Outline of the Nausea Problem.
  • Paul Andrews (UK). Neurophysiology and Neuropharmacology Specifically Related to Nausea.
  • Rebecca Clark‐Snow (USA), Richard J. Gralla (USA), and Paul Hesketh (USA). Methods of Measuring Nausea Utilizing Visual Analog and Categorical Scales, and Their Correlation with Emesis.
  • Martin Lesser (USA). Biostatistical Considerations.
  • Fausto Roila (Italy). Trial Design Methodology and Considerations.
  • Haralambos Raftopoulos (USA). Potential Cinical Trials Designed to Examine Nausea Associated with Dhemotherapy.

Conducting Clinical Trials With Promising Cancer Cachexia/Anorexia Agents
Chaired by Florian Strasser and Aminah Jatoi

This workshop, presented by the Nutrition and Cachexia Study Group, addressed the clinical trial literature pertaining to promising cancer anorexia/cachexia agents. The workshop provided an overview of issues and problems that arise when conducting such agents as well as considering some of the more promising agents in this area of nutrition.

  • Eduardo Bruera (USA). Why Should be Strive to Treat Cancer Cachexia?
  • Florian Strasser, (Switzerland). Phase I Testing of New Agents for Cancer Cachexia.
  • Martin Chasen (Canada). Do We Really Need Phase II Studies for Testing Novel Orexigenic Agents?
  • Aminah Jatoi (USA). Mounting a Phase III Study in Cancer Cachexia.
  • Discussion: Aminah Jatoi (USA), Stefan D. Anker (Germany)
  • Stefan D. Anker (Germany). SCWD‐Project Standards for Clinical Trials in Cancer Cachexia.
  • Eduardo Bruera (USA). Interacting with Pharmaceutical Companies in Drug Development.
  • General Discussion: What Do Regulatory Agencies Look for in Deciding on Cancer Cachexia Drug Approval?
  • Florian Strasser (Switzerland), Aminah Jatoi (USA), Concluding Discussion: Integrating Cachexia Trials in Oncology Care.

Survivorship Issues Of Adults Who Have Had A Childhood Cancer: How Does It Affect One’s Life?

This workshop, presented jointly by the Pediatrics Study Group and the Rehabilitation, Quality of Life, and Survivorship Study Group, addressed the importance of providing survivorship education and monitoring the late effects of childhood cancer. The workshop focused on service delivery and quality of life in long-term survivorship of adults who have had cancer in childhood. Topics included cardiac toxicity, methods of fertility preservation in males, the need for psychological input in survivorship care, and models of follow-up. 

  • Leontien C. Kremer (The Netherlands). Cardiac Toxicity and Late Effects.
    Moderators:  Paul Jacobsen and Marianne van de Wetering
  • Andreas Meissner (The Netherlands). New Methods of Fertility Preservation in Male Patients. 
    Moderator:  Wim Tissing 
  • L. Edwards (UK). Distress Thermometer to Measure the Need for Psychological Input in Survivorship Care of Young People. 
    Moderator: Paul Jacobsen and Faith Gibson 
  • W. Cheung, New Models of Follow‐up: Patient Passport. 
    Moderator: R. Doll and Wim Tissing